Quanzhou Maternity and Children's Hospital, Department of Neonatology, Quanzhou, 362000, Fujian Province, China.
Shanghai Children's Hospital, Department of Neonatology, Affiliated Children's Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, 200062, China.
Eur J Pediatr. 2024 Feb;183(2):689-696. doi: 10.1007/s00431-023-05336-y. Epub 2023 Nov 16.
To investigate the efficacy and safety of continuous blood purification (CBP) in neonates with septic shock and acute kidney injury (AKI). This retrospective study was conducted at two tertiary care children's hospitals between January 2015 and May 2022. A total of 26 neonates with septic shock and AKI were included in this study, with a mortality rate of 50%. Fourteen neonates (53.8%) received continuous veno-venous hemodiafiltration, and 12 (46.2%) received continuous veno-venous hemofiltration. Compared with the indices before CBP, urine output increased 12 h after CBP initiation (P = 0.003) and serum creatinine decreased (P = 0.019). After 24 h of CBP, blood urea nitrogen had decreased (P = 0.006) and mean arterial pressure had increased (P = 0.007). At the end of CBP, the vasoactive-inotropic score and blood lactate were decreased (P = 0.035 and 0.038, respectively) and PH was increased (P = 0.015). Thrombocytopenia was the most common complication of CBP. Conclusion: CBP can efficiently maintain hemodynamic stability, improve renal function, and has good safety in neonates with septic shock and AKI. However, the mortality rate remains high, and whether CBP improves the prognosis of neonates with septic shock and AKI remains unclear. What is Known: • Over 50% of children with septic shock have severe AKI, of which 21.6% required CBP. • The clinical application of CBP in septic shock has attracted increasing attention. What is New: • CBP can efficiently maintain hemodynamic stability, improve renal function, and has good safety in neonates with septic shock and AKI. • The mortality rate in neonates with septic shock and AKI receiving CBP remains high.
探讨连续血液净化(CBP)在感染性休克合并急性肾损伤(AKI)新生儿中的疗效和安全性。
这是一项回顾性研究,在 2015 年 1 月至 2022 年 5 月期间在两家三级儿童保健院进行。共纳入 26 例感染性休克合并 AKI 的新生儿,死亡率为 50%。14 例新生儿(53.8%)接受连续静脉-静脉血液透析滤过治疗,12 例(46.2%)接受连续静脉-静脉血液滤过治疗。与 CBP 前指标相比,CBP 开始后 12 小时尿量增加(P=0.003),血清肌酐降低(P=0.019)。CBP 后 24 小时,血尿素氮下降(P=0.006),平均动脉压升高(P=0.007)。CBP 结束时,血管活性-正性肌力评分和血乳酸降低(P=0.035 和 0.038),pH 值升高(P=0.015)。CBP 最常见的并发症是血小板减少症。
CBP 可有效维持血流动力学稳定,改善肾功能,在感染性休克合并 AKI 的新生儿中具有良好的安全性。然而,死亡率仍然很高,CBP 是否能改善感染性休克合并 AKI 新生儿的预后尚不清楚。
• 超过 50%的感染性休克患儿有严重 AKI,其中 21.6%需要 CBP。
• CBP 在感染性休克中的临床应用引起了越来越多的关注。
• CBP 可有效维持血流动力学稳定,改善肾功能,在感染性休克合并 AKI 的新生儿中具有良好的安全性。
• 接受 CBP 的感染性休克合并 AKI 新生儿死亡率仍然很高。